Hyeonji Kim

Hyeonji Kim

Auto-generated profile, based on publicly available information

Hyeonji Kim

Bertis R&D Division, Bertis Inc, Gyeonggi-do, Republic of Korea

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2024 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
HKHyeonji Kim
Hyeonji Kim
SHSunghyun Huh
Sunghyun Huh
JPJungkap Park
Jungkap Park
YHYoungmin Han
Youngmin Han
KAKyung-Geun Ahn
Kyung-Geun Ahn
UKUn-Beom Kang
Un-Beom Kang
Pancreatic ductal adenocarcinoma (PDAC) suffers from a lack of an effective diagnostic method, which hampers improvement in patient survival. Carbohydrate antigen 19-9 (CA19–9) is the only FDA-approved blood biomarker for PDAC, yet its clinical utility is limited due to suboptimal performance. Liquid chromatography-mass spectrometry (LC-MS) has emerged as a burgeoning technology in clinical proteomics for the discovery, verification, and validation of novel biomarkers. A plethora of protein biomarker candidates for PDAC have been identified using LC-MS, yet few has successfully transitioned into clinical practice. This translational standstill is owed partly to insufficient considerations of practical needs and perspectives of clinical implementation during biomarker development pipelines, such as demonstrating the analytical robustness of proposed biomarkers which is critical for transitioning from research-grade to clinical-grade assays. Moreover, the throughput and cost-effectiveness of proposed assays ought to be considered concomitantly from the early phases of the biomarker pipelines for enhancing widespread adoption in clinical settings. Here, we developed a fit-for-purpose multi-marker panel for PDAC diagnosis by consolidating analytically robust biomarkers as well as employing a relatively simple LC-MS protocol. In the discovery phase, we comprehensively surveyed putative PDAC biomarkers from both in-house data and prior studies. In the verification phase, we developed a multiple-reaction monitoring (MRM)-MS-based proteomic assay using surrogate peptides that passed stringent analytical validation tests. We adopted a high-throughput protocol including a short gradient (<10 min) and simple sample preparation (no depletion or enrichment steps). Additionally, we developed our assay using serum samples, which are usually the preferred biospecimen in clinical settings. We developed predictive models based on our final panel of 12 protein biomarkers combined with CA19-9, which showed improved diagnostic performance compared to using CA19-9 alone in discriminating PDAC from non-PDAC controls including healthy individuals and patients with benign pancreatic diseases. A large-scale clinical validation is underway to demonstrate the clinical validity of our novel panel.

1 January 2024 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
KYKyung-Hwak Yoon
Kyung-Hwak Yoon
HCHyosub Chu
Hyosub Chu
HKHyeonji Kim
Hyeonji Kim
SHSunghyun Huh
Sunghyun Huh
EKEun-Kyu Kim
Eun-Kyu Kim
HSHee-Chul Shin
Hee-Chul Shin
Yoon KH, et al. Ann Surg Treat Res. 2024 Apr;106(4):195-202. https://doi.org/10.4174/astr.2024.106.4.195